MedPath

Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients

Phase 2
Suspended
Conditions
HIV Infections
Registration Number
NCT00004998
Lead Sponsor
Agouron Pharmaceuticals
Brief Summary

The purpose of this study is to see if two different doses of AG1549 plus other anti-HIV drugs are safe and effective in HIV-infected patients who are not taking anti-HIV drugs.

Detailed Description

\[Note: As of 2/28/2001, due to toxicity studies and concerns for safety, sites were notified that they need to discontinue patients from the capravirine/placebo arms and continue patients with their background therapies or switch patients to new therapies, as deemed appropriate by the investigators.\] Patients are randomized to receive one of two doses of AG1549 plus Viracept (nelfinavir) plus Combivir (zidovudine/lamivudine). Patients remain on their assigned therapy for 48 weeks, with a follow-up visit at 28 to 35 days after the last dose of study medication. Blood samples are taken regularly to quantify HIV-1 RNA, CD4 and CD8 counts, peripheral blood mononuclear cells (PBMC), AG1549, Viracept, and M8 plasma concentrations. Physical exams, safety assessments, and other tests are also done throughout the study. On Day 8 and at the end of Week 48, pharmacokinetic samples are collected at 0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, and 12.0 hours postdose. At the end of Weeks 4, 8, 16, 24, and 36, pharmacokinetic samples are taken prior to dosing and between 2 to 4 hours post-dose.

Recruitment & Eligibility

Status
SUSPENDED
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (10)

AIDS Research Consortium of Atlanta

πŸ‡ΊπŸ‡Έ

Atlanta, Georgia, United States

Beth Israel Deaconess Med Ctr

πŸ‡ΊπŸ‡Έ

Boston, Massachusetts, United States

Anderson Clinical Research

πŸ‡ΊπŸ‡Έ

Pittsburgh, Pennsylvania, United States

Community Health Care

πŸ‡ΊπŸ‡Έ

Fort Lauderdale, Florida, United States

South Shore Hosp

πŸ‡ΊπŸ‡Έ

Miami, Florida, United States

Catholic Med Ctr

πŸ‡ΊπŸ‡Έ

Jamaica, New York, United States

Immunity Care and Research Inc

πŸ‡©πŸ‡΄

Santo Domingo, Dominican Republic

Liberty Medical

πŸ‡ΊπŸ‡Έ

New York, New York, United States

Clin Research of West Florida

πŸ‡ΊπŸ‡Έ

Clearwater, Florida, United States

Infectious Diseases Associates

πŸ‡ΊπŸ‡Έ

Sarasota, Florida, United States

Β© Copyright 2025. All Rights Reserved by MedPath